Bicycle Therapeutics (BCYC) vs Lifecore Biomedical (LFCR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Lifecore Biomedical (LFCR) has outperformed Bicycle Therapeutics (BCYC) over the past year, losing 1.7% versus a loss of 57.6%. Over five years, LFCR leads with a -32.8% price change compared with -93.7% for BCYC. Bicycle Therapeutics is the larger company by market cap ($242.2 million vs $241.8 million), about 1.0 times the size.
Lifecore Biomedical converts more of its revenue into profit, with a net margin of -30.0% versus -301.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BCYC | LFCR |
|---|---|---|
| Share price | $3.46 | $6.38 |
| Market cap | $242.18M | $241.84M |
| 1-day change | -3.89% | -0.93% |
| YTD return | -51.13% | -22.00% |
| 1-year return | -57.65% | -1.69% |
| 5-year return | -93.65% | -32.84% |
| EPS (TTM) | $-2.73 | $-1.27 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $72.59M | $128.87M |
| Revenue growth (YoY) | +105.77% | +0.47% |
| Net income (latest FY) | $-218.96M | $-38.72M |
| Gross margin | — | 31.27% |
| Operating margin | -340.38% | -13.38% |
| Net margin | -301.66% | -30.04% |
| 52-week high | $9.08 | $8.98 |
| 52-week low | $3.33 | $3.63 |
| Distance from 52-week high | -61.89% | -28.95% |
| Analyst consensus | none | hold |
| Avg. price target upside | +174.57% | -1.57% |
| Average volume | 392.27K | 330.83K |
| Shares outstanding | 50.55M | 37.91M |
| Employees | 288 | 382 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LFCR has outperformed BCYC by 56.0 percentage points over the past year.
- Lifecore Biomedical is more profitable, keeping -30.0 cents of every revenue dollar as net income versus -301.7 cents for Bicycle Therapeutics.
- Bicycle Therapeutics grew revenue faster in its latest fiscal year (+105.77% vs +0.47%).
About Bicycle Therapeutics
BCYC stock →Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137; and BT1702, a theranostic BRC molecule targeting MT1-MMP for which IND-enabling activities are ongoing.
Health Care · Biotechnology: Pharmaceutical Preparations · 288 employees
About Lifecore Biomedical
LFCR stock →Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities.
Health Care · Biotechnology: Pharmaceutical Preparations · 382 employees
BCYC vs LFCR FAQ
Which is bigger, Bicycle Therapeutics or Lifecore Biomedical?
Bicycle Therapeutics (BCYC) is larger, with a market capitalization of $242.18M compared with $241.84M for Lifecore Biomedical (LFCR).
Which stock has performed better over the past year, BCYC or LFCR?
LFCR returned -1.69% over the past 12 months, compared with -57.65% for BCYC (price return, excluding dividends). Past performance does not predict future results.
Are Bicycle Therapeutics and Lifecore Biomedical in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.